Free Trial

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Pharmacist checking stock values; Pharma stocks overview.

Key Points

  • Johnson & Johnson, Novartis, Bristol-Myers Squibb, Merck, Eli Lilly and Amgen are among the drugmakers targeted in upcoming Medicare price negotiations.
  • High prescription drug costs in the U.S. are a popular political concern, but the pharmaceutical industry argues that lowering prices could hinder research and development.
  • The pharmaceutical industry remains highly regulated and subject to government influence, but competition and innovation mean new products are always in the pipeline.
  • MarketBeat previews top five stocks to own in November.

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJNovartis AG NYSE: NVSBristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRKEli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year’s Medicare price negotiations.

The move is part of the Inflation Reduction Act, which allows the federal government to negotiate prices of certain drugs for Medicare.

Reducing drug prices in the U.S. is a popular platform for politicians. It’s well known that high prescription drug costs can disproportionately burden retirees and many others. U.S. consumers pay higher prices for drugs than patients in many other countries worldwide, and that financial burden takes a toll on retirees and many others. 

However, for its part, the global pharmaceutical industry argues that reducing consumer costs would compromise its research and development capabilities, hindering the discovery of new technologies. The industry also cites high costs of manufacturing. 

Drugmakers Firing Back with Lawsuits

Johnson & Johnson, Merck, Bristol-Myers Squibb and Japan-based Astellas Pharma OTCMKTS: ALPMY, maker of cancer treatments, filed federal lawsuits saying the law allowing Medicare to pay less for some drugs is unconstitutional.   

The drama will likely take years to play out. Any changes to Medicare-negotiated prices wouldn’t go into effect until 2026. Likewise, pharma companies’ lawsuits will wend their way through the federal court system at a glacial pace. 

Of course, investors will pay attention, although the highly regulated pharmaceutical industry is always subject to Washington’s whims. 

For example, Horizon Therapeutics Public Limited Co. NASDAQ: HZNP are up 5.94% for the week after the Federal Trade Commission ended its attempt to block Amgen’s acquisition of the Ireland-based drug maker.

While regulators have a role in overseeing drug safety, pharmaceutical companies are also under scrutiny for pricing practices. The industry is highly profitable, giving regulators who hope to score points with the public an added incentive to step in. 

Pharma Industry ETFs Post Gains

The SPDR S&P Pharmaceuticals ETF NYSEARCA: XPH is up 1.85% for the week, although its year-to-date gain of 7.97% suggests investors are at least sanguine about the wider industry’s prospects. 

The wider S&P healthcare sector, as tracked by the Health Care Select Sector SPDR Fund NYSEARCA: XLV, has declined by 0.76% this year, lagging the broader S&P 500 index, which has returned 17.59%. 

So will the Medicare negotiations result in lower prices for pharmaceuticals? 

For a time, investors may be reluctant to pile into those stocks very aggressively. However, pharmaceuticals are constantly innovating and bringing new products to market, frequently licensing or buying outright technologies developed by biotech startups.

In other words, the industry isn’t exactly stagnant. 

Along those lines, some drugs on that list aren’t their parent companies' key revenue growth drivers. 

Drugmakers Already Face Ongoing Challenges

One reason the cuts, if they happen, may not put much of a dent in pharma stock prices is competition: Already, drug companies have their own versions of popular products. For example, Novo Nordisk A/S NYSE: NVO Ozempic weight-loss drug competes with Lilly’s Mounjaro. 

Neither is on the list of Medicare-targeted drugs. 

Competition from generic substitutes is also an ongoing reality, as patents for branded medications regularly expire. 

Several drugs on the targeted list will lose their patent exclusivity in 2026 or 2027, shortly after the new law would go into effect, meaning the financial impact of lower Medicare prices may be limited. 

It's improbable that pharmaceutical stocks, as a whole, will undergo a sharp downturn solely because there’s a threat that Medicare pricing may be lower in three years. While price reductions down the road may affect specific drug manufacturers, the pharmaceutical industry has plenty of opportunity for growth in the coming years due to portfolio diversification and innovation. 

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Kate Stalter
About The Author

Kate Stalter

Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Amgen (AMGN)
4.539 of 5 stars
$298.811.0%3.19%24.43Hold$305.50
Bristol Myers Squibb (BMY)
4.9679 of 5 stars
$43.630.5%5.68%17.59Hold$57.23
Eli Lilly and Company (LLY)
4.9751 of 5 stars
$803.53-1.9%0.75%52.52Moderate Buy$939.12
Health Care Select Sector SPDR Fund (XLV)N/A$143.270.7%1.70%21.15Moderate Buy$143.27
Horizon Therapeutics Public (HZNP)N/A$116.30flatN/A62.19N/AN/A
Johnson & Johnson (JNJ)
4.8475 of 5 stars
$193.270.6%2.69%18.65Moderate Buy$199.88
Merck & Co., Inc. (MRK)
4.9993 of 5 stars
$84.781.0%3.82%13.06Hold$104.33
Novartis (NVS)
2.526 of 5 stars
$131.460.5%1.98%19.13Hold$120.33
Novo Nordisk A/S (NVO)
4.3751 of 5 stars
$54.41-3.0%1.51%14.95Moderate Buy$76.00
SPDR S&P Pharmaceuticals ETF (XPH)N/A$48.200.4%1.04%14.28Moderate Buy$48.20
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Related Videos

AI vs. Wall Street: 5 Names It Loves Right Now
Markets Are Sliding: Where to Find Opportunity
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines